The U.S. Food and Drug Administration has approved GlaxoSmithKline’s 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy.
The B-lymphocyte stimulator-specific inhibiting monoclonal antibody was previously approved for children aged 5 years and older via intravenous administration by health care professionals.
With this approval, a child’s health care provider can determine if at-home administration is appropriate, and if so, the patient’s caregiver can administer the medicine at home via an autoinjector once per week for children who weigh ≥40 kg or once every two weeks for children who weigh 15 kg to
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medical Xpress – https://medicalxpress.com/news/2024-05-fda-belimumab-autoinjector-pediatric-lupus.html
